Jun 26, 2026 7:40 am EDT OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
Jun 08, 2026 6:00 am EDT OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Jun 02, 2026 6:00 am EDT OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
May 29, 2026 7:20 am EDT OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
May 18, 2026 6:30 am EDT OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
May 15, 2026 4:05 pm EDT OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026